2013, Number 2
<< Back Next >>
Gac Med Mex 2013; 149 (2)
Bonecancer pain: from preclinicalpharmacology toclinical trials
Montiel-Ruiz RM, Acosta-González RI, Jiménez AJM
Language: Spanish
References: 48
Page: 204-211
PDF size: 198.81 Kb.
ABSTRACT
Worldwide over 12 million people were diagnosed with cancer (excluding non-melanoma skin cancer) and 8 million
individuals died from cancer in 2008. Recent data indicate that 75-90% of patients with advanced stage diseases or
metastatic cancer will experience significant cancer pain. Bone cancer pain is common in patients with advanced breast,
prostate, and lung cancer as these tumors have a marked affinity to metastasize to bone. Once tumors metastasize to
bone, they are a major cause of morbidity and mortality as the tumor induces significant skeletal remodeling, fractures,
pain and anemia; all of which reduce the functional status, quality of life and survival of the patient. Currently, the factors
that drive cancer pain are poorly understood, however, several recently introduced models of bone cancer pain that
mirror the human condition, are providing insight into the mechanisms that drive bone cancer pain and guiding the
development of novel therapies to treat the cancer pain. Several of these therapies have recently been approved by
the FDA to treat bone cancer pain (bisphosphonates, denosumab) and others are currently being evaluated in human
clinical trials (tanezumab). These new mechanism-based therapies are enlarging the repertoire of modalities available
to treat bone cancer pain and improving the quality of life and functional status of patients with bone cancer.
REFERENCES
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90. Epub 2011/02/08.
Khan N, Afaq F, Mukhtar H. Lifestyle as risk factor for cancer: evidence from human studies. Cancer Lett. 2010;293(2):133-43. Epub 2010/01/19.
Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300. Epub 2010/07/09.
Costantini M, Ripamonti C, Beccaro M, et al. Prevalence, distress, management, and relief of pain during the last 3 months of cancer patients’ life. Results of an Italian mortality follow-back survey. Ann Oncol. 2009;20(4):729-35. Epub 2009/01/24.
Van den Beuken-Van Everdingen MH, De Rijke JM, Kessels AG, Schouten HC, Van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007;18(9):1437-49. Epub 2007/03/16.
Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12(20 Pt 2):6243s-9s.
Dy SM, Asch SM, Naeim A, Sanati H, Walling A, Lorenz KA. Evidencebased standards for cancer pain management. J Clin Oncol. 2008;26(23): 3879-85.
Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain. 1997;69(1-2):1-18.
Casuccio A, Mercadante S, Fulfaro F. Treatment strategies for cancer patients with breakthrough pain. Expert Opin Pharmacother. 2009;10(6):947-53. Epub 2009/04/09.
Coleman RE. Skeletal complications of malignancy. Cancer. 1997;80 Suppl 8:1588-94.
Desandre PL, Quest TE. Management of cancer-related pain. Emerg Med Clin North Am. 2009;27(2):179-94. Epub 2009/05/19.
Montagnini ML, Zaleon CR. Pharmacological management of cancer pain. J Opioid Manag. 2009;5(2):89-96. Epub 2009/06/11.
Honore P, Luger NM, Sabino MA, et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med. 2000;6(5):521-8.
Schwei MJ, Honore P, Rogers SD, et al. Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci. 1999;19(24):10886-97.
Sabino MA, Ghilardi JR, Jongen JL, et al. Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2. Cancer Res. 2002;62(24):7343-9.
Sabino M, Luger N, Mach D, et al. Different tumors in bone each give rise to a distinct pattern of skeletal destruction, bone cancer-related pain behaviors and neurochemical changes in the central nervous system. Int J Cancer. 2003;104(5):550-8.
Jiménez-Andrade JM, Bloom AP, Stake JI, et al. Pathological sprouting of adult nociceptors in chronic prostate cancer-induced bone pain. J Neurosci. 2010;30(44):14649-56. Epub 2010/11/05.
Bloom AP, Jiménez-Andrade JM, Taylor RN, et al. Breast cancer-induced bone remodeling, skeletal pain and sprouting of sensory nerve fibers. J Pain. 2011;12(6):698-711. Epub 2011/04/19.
Griffiths JR. Are cancer cells acidic? Br J Cancer. 1991;64:425-7.
Clohisy DR, Perkins SL, Ramnaraine ML. Review of cellular mechanisms of tumor osteolysis. Clin Orthop Rel Res. 2000;373:104-14.
Ghilardi JR, Rohrich H, Lindsay TH, et al. Selective blockade of the capsaicin receptor TRPV1 attenuates bone cancer pain. J Neurosci. 2005;25(12):3126-31.
Von Moos R, Strasser F, Gillessen S, Zaugg K. Metastatic bone pain: treatment options with an emphasis on bisphosphonates. Support Care Cancer. 2008;16(10):1105-15. Epub 2008/08/07.
Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132-9. Epub 2010/11/10.
Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29(9):1125-32. Epub 2011/02/24.
Clohisy DR, Mantyh PW. Bone cancer pain and the role of RANK-L/OPG. J Musculoskelet Neuronal Interact. 2004;4(3):293-300.
Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000;88 Suppl 12:2961-78.
Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol. 2009;27(10):1564-71. Epub 2009/02/25.
Jiménez-Andrade JM, Martin CD, Koewler NJ, et al. Nerve growth factor sequestering therapy attenuates non-malignant skeletal pain following fracture. Pain. 2007;133(1-3):183-96. Epub 2007/08/19.
Rubert Cynthia HR, Malawer M. Orthopedic management of skeletal metastases. In: Body JJ, ed. Tumor bone disease and osteoporosis in cancer patients. New York City: Marcel Dekker; 2000. p. 305-56.
Arrington SA, Schoonmaker JE, Damron TA, Mann KA, Allen MJ. Temporal changes in bone mass and mechanical properties in a murine model of tumor osteolysis. Bone. 2006;38(3):359-67. Epub 2005/11/10.
Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009;9(4):239-52. Epub 2009/03/13.
Mantyh PW. Cancer pain and its impact on diagnosis, survival and quality of life. Nat Rev Neurosci. 2006;7(10):797-809.
Julius D, Basbaum AI. Molecular mechanisms of nociception. Nature. 2001;413(6852):203-10.
Pezet S, McMahon SB. Neurotrophins: mediators and modulators of pain. Annu Rev Neurosci. 2006;29:507-38.
Gould HJ 3rd, Gould TN, England JD, Paul D, Liu ZP, Levinson SR. A possible role for nerve growth factor in the augmentation of sodium channels in models of chronic pain. Brain Res. 2000;854(1-2):19-29.
Ji RR, Samad TA, Jin SX, Schmoll R, Woolf CJ. p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron. 2002;36(1):57-68.
Jiménez-Andrade JM, Ghilardi JR, Castaneda-Corral G, Kuskowski MA, Mantyh PW. Preventive or late administration of anti-NGF therapy attenuates tumor-induced nerve sprouting, neuroma formation, and cancer pain. Pain. 2011;152(11):2564-74. Epub 2011/09/13.
Sevcik MA, Ghilardi JR, Peters CM, et al. Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization. Pain. 2005;115(1-2):128-41. Epub 2005/04/20.
Halvorson KG, Kubota K, Sevcik MA, et al. A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. Cancer Res. 2005;65(20):9426-35.
Ghilardi JR, Freeman KT, Jiménez-Andrade JM, et al. Administration of a tropomyosin receptor kinase inhibitor attenuates sarcoma-induced nerve sprouting, neuroma formation and bone cancer pain. Molecular Pain. 2010;6(87).
Peters CM, Ghilardi JR, Keyser CP, et al. Tumor-induced injury of primary afferent sensory nerve fibers in bone cancer pain. Exp Neurol. 2005;193(1):85-100. Epub 2005/04/09.
Devor M, Govrin-Lippmann R, Angelides K. Na+ channel immunolocalization in peripheral mammalian axons and changes following nerve injury and neuroma formation. J Neurosci. 1993;13(5):1976-92. Epub 1993/05/01.
Black JA, Nikolajsen L, Kroner K, Jensen TS, Waxman SG. Multiple sodium channel isoforms and mitogen-activated protein kinases are present in painful human neuromas. Ann Neurol. 2008;64(6):644-53. Epub 2008/12/25.
Devor M. Neuropathic pain: what do we do with all these theories? Acta Anaesthesiol Scand. 2001;45(9):1121-7. Epub 2001/10/31.
Mantyh WG, Jiménez-Andrade JM, Stake JI, et al. Blockade of nerve sprouting and neuroma formation markedly attenuates the development of late stage cancer pain. Neuroscience. 2010;171(2):588-98. Epub 2010/09/21.
Elitt CM, McIlwrath SL, Lawson JJ, et al. Artemin overexpression in skin enhances expression of TRPV1 and TRPA1 in cutaneous sensory neurons and leads to behavioral sensitivity to heat and cold. J Neurosci. 2006;26(33):8578-787.
Schweizerhof M, Stosser S, Kurejova M, et al. Hematopoietic colonystimulating factors mediate tumor-nerve interactions and bone cancer pain. Nat Med. 2009;15(7):802-7. Epub 2009/06/16.
Jimenez-Andrade JM, Mantyh WG, Bloom AP, Ferng AS, Geffre CP, Mantyh PW. Bone cancer pain. Ann N Y Acad Sci. 2010;1198:173-81. Epub 2010/06/12.
Full text